H5N1 News and Research

Latest H5N1 News and Research

Sinovac Biotech receives a revised production license for its Panflu.1 vaccine

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.

18 Nov 2009

Asuragen enters into an exclusive agreement with Life Technologies

Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML).

18 Nov 2009

New Web-based application for tracking the H1N1 flu virus across the globe

New methods of studying avian influenza strains and visually mapping their movement around the world will help scientists more quickly learn the behavior of the pandemic H1N1 flu virus, Ohio State University researchers say.

17 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

Puricore reports increase in sales of 25% in Q3

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009.

3 Nov 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.

27 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Wildlife Conservation Society to monitor diseases for preventing global pandemic

The Wildlife Conservation Society will play a key role in a new international effort to monitor diseases that move between animals and people in order to prevent the next global pandemic.

24 Oct 2009

UC Davis' international effort to prevent new pandemics

In hopes of preventing the next global pandemic and a possible death toll into the millions, UC Davis today launches an unprecedented international effort to find and control diseases that move between wildlife and people.

24 Oct 2009

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014.

23 Oct 2009

Adjuvanted and non-adjuvanted H1N1 vaccines safe for pregnant women, say Canadian experts

After discussion with the Public Health Agency of Canada, and based on the evidence for other adjuvanted vaccines as well as experience around the world to date with the adjuvanted H1N1 vaccine, Canadian experts say that both the adjuvanted and non-adjuvanted H1N1 vaccines are safe for pregnant women.

23 Oct 2009

Emerging Pandemic Threats program to combat newly emerging diseases of animal origin

The United States Agency for International Development (USAID) is launching an Emerging Pandemic Threats (EPT) program that builds on the successes of the Agency's long-standing programs in disease surveillance, training, and outbreak response, particularly those addressing avian and pandemic influenza.

22 Oct 2009

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Aethlon Medical, Inc. announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.

21 Oct 2009

Rice University scientists win NIH stimulus funds to study influenza A

Rice University scientists have won a $1.5 million grant from the National Institutes of Health to scrutinize the influenza A virus for clues that could lead to more effective antiviral drugs. Strains of influenza A include this year's pandemic H1N1 variety, some seasonal varieties and the much-feared H5N1 bird flu.

21 Oct 2009

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.

20 Oct 2009

CytoSorb human clinical trials nearing completion

TapeBeat.com, the news and research portal for the serious bio-tech investor in conjunction with the Farseers Group is proud to profile one of the most exciting up and coming biotech companies, MedaSorb Technologies (MSBT.OB), which is perfectly poised to realize exponential growth.

19 Oct 2009